Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TAR DNA binding protein pseudogene 2 (**TARDBPP2**) is a genomic sequence sharing high similarity with the functional TARDBP gene but lacks the ability to encode, transcribe, or translate a functional protein product. Pseudogenes such as TARDBPP2 may result from duplication or retrotransposition events in evolution but are generally considered nonfunctional in protein-coding capacity[6]. While the parental TARDBP gene and its protein product TDP-43 are critical for RNA processing, splicing, and have been implicated in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, there is no evidence that TARDBPP2 has a direct physiological or pathological activity, nor is it a current or probable therapeutic target[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TAR DNA binding protein pseudogene 2 (TARDBPP2).